Galecto terminates development for its lead candidate
Galecto has axed the development of its lead pipeline candidate, GB0139, after announcing that the Phase IIb trial for the…
Trial Termination
-
-
Palisade Bio terminates its post-surgical abdominal adhesions treatment trial
Palisade Bio has terminated the development of its lead clinical candidate, tranexamic acid (LB1148), for reducing intra-abdominal adhesions in patients…
